Canbex Therapeutics Ltd   Report issue

For profit Phase 2
Founded: London United Kingdom (2005)
Status: Acquired by Ipsen (2015)

Organization Overview

First Clinical Trial
2015
NCT02542787
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2015

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Phase 2 Trials (1)

vsn16r (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Multiple Sclerosis (Phase 2)

Muscle Spasticity (Phase 2)

Sclerosis (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 1